^
Association details:
| Biomarker: | PTEN mutation |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) + AZD8055 (mTOR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 660: Combination of mTOR kinase inhibitors with Src inhibitors in PTEN-mt prostate cancer cells
Published date:
05/15/2020
Excerpt:
These data indicate that adding AZD8055 to dasatinib may achieve better treatment outcomes in PTEN-mt prostate cancer models. Such combination modality hold potential for future development as a novel strategy for PTEN-mutated prostate cancer patients who are less responsive to Src inhibitors.
DOI:
10.1158/1538-7445.AM2020-660
